Abstract
Many IV antiepileptic drugs administered in emergency situations to patients with prolonged seizures have serious adverse effects. For this reason, the authors conducted a multicenter, open-label, prospective, dose-escalation study of IV valproate sodium administered to patients with epilepsy at rates of infusion of up to 6 mg/kg/minute and doses of up to 30 mg/kg. Valproate sodium had no clinically significant negative effects on blood pressure and pulse rate and caused only mild-to-moderate, reversible adverse events.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Acute Disease
-
Anticonvulsants / administration & dosage*
-
Anticonvulsants / adverse effects
-
Anticonvulsants / pharmacokinetics
-
Blood Pressure / drug effects
-
Blood Pressure / physiology
-
Cohort Studies
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Epilepsy / drug therapy*
-
Heart Rate / drug effects
-
Heart Rate / physiology
-
Humans
-
Infusions, Intravenous / methods
-
Prospective Studies
-
Status Epilepticus / drug therapy*
-
Status Epilepticus / prevention & control
-
Time Factors
-
Treatment Outcome
-
Valproic Acid / administration & dosage*
-
Valproic Acid / adverse effects
-
Valproic Acid / pharmacokinetics
Substances
-
Anticonvulsants
-
Valproic Acid